|
|
|
| Efficacy of Loratadine Combined with Levocetirizine in the Treatment of Chronic Refractory Urticaria in Children and Its Effects on Levels of Serum IgE and IFN-γ |
| LIAO Xueli, ZHU Canyang, MAI Biwei, et al |
| Hainan Women and Children' s Medical Center, Hainan Haikou 570100, China |
|
|
|
|
Abstract Objective: To investigate the efficacy of loratadine combined with levocetirizine in the treatment of chronic refractory urticarial (CRU) in children and its effects on levels of serum IgE and IFN-γ. Methods: A total of 151 children patients with CRU who were treated in the hospital between January 2018 and January 2021 were selected as observation subjects. According to the simple randomization of the random number table method, the patients were divided into mono-drug group (75 cases) and combined drug group (76 cases). The children patients in mono-drug group were administered levocetirizine oral liquid, and the children patients in combined drug group were treated with loratadine combined with levocetirizine. The clinical efficacy, clinical symptoms scores, T lymphocyte subsets(CD3+,CD4+,CD8+and CD4+/CD8+), immunoglobulin E(IgE)and serum cytokines[interleukin-4(IL-4), interleukin-13(IL-13), interferon-γ(IFN-γ)]were compared between the two groups of children patients after treatment, and the adverse reactions rates were statistically analyzed in the two groups. Results: After treatment, the total effective rate of children in combined group was significantly higher than that in mono-drug group (93.42%vs 81.33%)(P<0.05). The scores of various clinical symptoms and total score of the two groups of children were significantly decreased compared with those before treatment, and the decreases in combined drug group were greater than those in mono-drug group (P<0.05). The CD3+ and CD8+ in the two groups were significantly increased compared to before treatment, and the increases were greater in combined drug group compared to mono-drug group (P<0.05). The CD4+ and CD4+/CD8+ were significantly reduced compared to before treatment, and the reductions were greater in combined drug group than those in mono-drug group (P<0.05). The levels of IgE,IL-4 and IL-13 in the two groups were significantly lower than those before treatment, and compared with mono-drug group, the decreases in combined drug group were greater (P<0.05). The level of IFN-γ was significantly higher than that before treatment, and the increase in combined drug group was higher than that in mono-drug group(P<0.05).The total incidence rate of adverse reactions was 9.21%in combined drug group and was 14.67% in mono-drug group, and the difference in adverse reaction rate between two groups was not statistically significant(P>0.05). Conclusion: Loratadine combined with levocetirizine has a significant clinical efficacy in the treatment of CRU in children, and it can improve the clinical symptoms and immune function disorders, and has medication safety.
|
|
|
|
|
|
[1] 赵隽乔,马铁明.以针刺为主治疗慢性荨麻疹的Meta分析[J].针刺研究,2020,45(1):66~73.
[2] 李云玲,郑惠文.1.5倍常规剂量氯雷他定联合转移因子口服液治疗儿童慢性难治性荨麻疹疗效观察[J].儿科药学杂志,2020,26(7):20~22.
[3] 韦菊梅,温斯健,包家娟,等.盐酸左西替利嗪对人毛乳头细胞生长影响的初步研究[J].中华皮肤科杂志,2019,(6):389~394.
[4] 宋红娟,王宝娟,李秋梅,等.灭荨汤联合抗组胺药物治疗慢性荨麻疹疗效及安全性评价[J].中华中医药学刊,2018,36(6):1515~1519.
[5] 谭凌玲.加用润燥止痒胶囊对慢性荨麻疹患者临床症状及血清总IgE、IL-4及外周血EOS、ECP水平的影响[J].湖南师范大学学报(医学版),2018,15(5):83~85.
[6] 寒宇阳,白丽霞,李垣君,等.1028例过敏性皮肤病患儿过敏原特异性IgE测定及分析[J].中国医师杂志,2019,21(9):1359~1362.
[7] 贵仁伍,任静,赵润,等.荆肤止痒颗粒联合左西替利嗪治疗儿童慢性荨麻疹的临床研究[J].现代药物与临床,2019,34(10):3026~3029.
[8] 周舒.左西替利嗪与复方甘草酸苷应用在慢性荨麻疹治疗中的临床效果研究[J].临床医药文献电子杂志,2019,6(3):163.
[9] 罗文峰,程喜平,王继辉,等.奥洛他定联合卡介菌多糖核酸对慢性荨麻疹患者的免疫应答机制探讨[J].中国现代医学杂志,2018,28(12):113~117.
[10] 付旭晖,吴丹丹,臧馥兰,等.硒酵母联合富马酸卢帕他定片治疗慢性荨麻疹临床疗效观察[J].中国皮肤性病学杂志,2020,34(4):485~488.
[11] 龙漫,曹春浩,郑洲,等.电针足三里通过调节Th1/Th2平衡改善迟发型过敏反应[J].湖北中医药大学学报,2018,20(1):24~27. |
|
|
|
2021, Vol. 27 
